Media coverage about Gilead Sciences (NASDAQ:GILD) has been trending somewhat positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Gilead Sciences earned a news sentiment score of 0.71 on their scale. InfoTrie also assigned press coverage about the biopharmaceutical company an news buzz score of 8 out of 10, meaning that recent news coverage is very likely to have an effect on the company’s share price in the near term.
Here are some of the news headlines that may have effected Gilead Sciences’ analysis:
- Gilead Sciences (GILD) Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting (streetinsider.com)
- Gilead Sciences (GILD) Announces Positive Phase 2 Results for GS-9674 in Primary PSC at The Liver Meeting (streetinsider.com)
- Gilead’s GS-9674 shows positive action in mid-stage NASH study (seekingalpha.com)
- Gilead Presents Data From Nonalcoholic Steatohepatitis (NASH) Development Program for Advanced Fibrosis at The Liver Meeting® 2018 (finance.yahoo.com)
- Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018 (finance.yahoo.com)
A number of research analysts have commented on the company. Wells Fargo & Co increased their target price on Gilead Sciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a report on Thursday, July 26th. Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a research report on Thursday, July 26th. Cantor Fitzgerald began coverage on Gilead Sciences in a research report on Monday, October 1st. They set an “overweight” rating and a $87.00 price target on the stock. BidaskClub upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. Finally, ValuEngine upgraded Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $87.84.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 EPS for the quarter, beating the consensus estimate of $1.63 by $0.21. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. The firm had revenue of $5.60 billion for the quarter, compared to analysts’ expectations of $5.44 billion. During the same period last year, the firm earned $2.27 EPS. Sell-side analysts predict that Gilead Sciences will post 6.44 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Thursday, December 13th. Gilead Sciences’s dividend payout ratio is currently 26.64%.
In related news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $69.55, for a total value of $3,477,500.00. Following the sale, the director now directly owns 3,067,762 shares in the company, valued at approximately $213,362,847.10. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 150,000 shares of company stock worth $11,087,500. 1.30% of the stock is owned by insiders.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Further Reading: How to calculate the intrinsic value of a stock
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.